Kura Oncology secures approvals for leukemia drug, its first

And Abbvie cuts ties with Google-backed longevity company, lays off scientists

November 14, 2025 Check out STAT+

Sponsored By

What's the five-letter name of Nigeria's largest city? Solve STAT's latest mini-crossword.

CDC STAT+ | Kura Oncology secures approval for leukemia drug, its first The FDA approved a drug made by Kura Oncology to treat patients with a certain type of genetically altered leukemia. It will be marketed as Komzifti. By Adam Feuerstein STAT+ | Why Richard Pazdur taking over the FDA's drug division is good for patients — and drug companies The Food and Drug Administration official has been able to approve new treatments more quickly, on less data, without sacrificing rigor By Matthew Herper STAT+ | AbbVie cuts ties with Google-backed longevity company, lays off scientists The pharma giant is severing a collaboration that began in 2014 with a $1.5 billion agreement to find longevity-boosting medicines. By Damian Garde Adobe STAT+ | U.K. releases plan to phase out animal testing in research Certain experiments will wind down in the coming years, as some scientists make the case for the continued importance of animal research. By Andrew Joseph

More around STAT

---

In case you missed it First-of-its-kind study may help explain why colorectal cancers are rising sharply in young people, CNN U.S. visas can be denied for obesity, cancer and diabetes, Secretary of State Marco Rubio says, Washington Post. "Certain medical conditions ... can require hundreds of thousands of dollars' worth of care." Listen: How mRNA Vaccines could transform cancer treatment, Scientific American

---

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Cancer Briefing? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser